Digital tobacco-cessation treatments hold great promise. But dedicated efforts will be required to promote access to and ...

Libtayo gained FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, promising improved ...

Regeneron gests US FDA approval for Libtayo as an adjuvant treatment of CSCC with a high risk of recurrence after surgery and radiation: Tarrytown, New York Friday, October 10, 20 ...

While immunotherapy targeting PD-1 or its ligand PD-L1 has transformed cancer treatment by overcoming T-cell exhaustion, only ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.

How one organization is tackling primary care issues by reducing burnout, building team-based models, and using technology to ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...

Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the PD-1 inhibitor Libtayo as an adjuvant ...

Bernstein and colleagues evaluated potential jurors’ perception of culpability of a radiologist in a hypothetical false-negative diagnosis malpractice case. 2. An increased perception of liability was ...

Preliminary findings for dopaminergic cell transplantation have reported positive trends towards safety and efficacy for people with Parkinson's disease (PD), according to two studies released at the ...